ImmunoGen, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "ImmunoGen, Inc. - Product Pipeline Review - 2014" provides data on the ImmunoGen, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, ImmunoGen, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoGen, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- ImmunoGen, Inc. - Brief ImmunoGen, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoGen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ImmunoGen, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ImmunoGen, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ImmunoGen, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ImmunoGen, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ImmunoGen, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ImmunoGen, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ImmunoGen, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ImmunoGen, Inc. Snapshot 5
ImmunoGen, Inc. Overview 5
Key Information 5
Key Facts 5
ImmunoGen, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
ImmunoGen, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
ImmunoGen, Inc. - Pipeline Products Glance 15
ImmunoGen, Inc. - Clinical Stage Pipeline Products 15
Phase I Products/Combination Treatment Modalities 15
ImmunoGen, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
ImmunoGen, Inc. - Drug Profiles 18
IMGN-289 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
IMGN-529 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IMGN-853 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
lorvotuzumab mertansine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PC-61 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
huHER3-8 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ImmunoGen, Inc. - Pipeline Analysis 26
ImmunoGen, Inc. - Pipeline Products by Therapeutic Class 26
ImmunoGen, Inc. - Pipeline Products by Target 27
ImmunoGen, Inc. - Pipeline Products by Route of Administration 28
ImmunoGen, Inc. - Pipeline Products by Molecule Type 29
ImmunoGen, Inc. - Pipeline Products by Mechanism of Action 30
ImmunoGen, Inc. - Recent Pipeline Updates 31
ImmunoGen, Inc. - Dormant Projects 36
ImmunoGen, Inc. - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
AVE-1642 37
AVE-9633 37
cantuzumab ravtansine 37
IMGN-388 37
lorvotuzumab mertansine 38
Oncolysin B 38
ImmunoGen, Inc. - Company Statement 39
ImmunoGen, Inc. - Locations And Subsidiaries 40
Head Office 40
ImmunoGen, Inc. - Key Manufacturing Facilities 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
ImmunoGen, Inc., Key Information 5
ImmunoGen, Inc., Key Facts 5
ImmunoGen, Inc. - Pipeline by Indication, 2014 8
ImmunoGen, Inc. - Pipeline by Stage of Development, 2014 9
ImmunoGen, Inc. - Monotherapy Products in Pipeline, 2014 10
ImmunoGen, Inc. - Partnered Products in Pipeline, 2014 11
ImmunoGen, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
ImmunoGen, Inc. - Out-Licensed Products in Pipeline, 2014 13
ImmunoGen, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
ImmunoGen, Inc. - Phase I, 2014 15
ImmunoGen, Inc. - Preclinical, 2014 16
ImmunoGen, Inc. - Discovery, 2014 17
ImmunoGen, Inc. - Pipeline by Therapeutic Class, 2014 26
ImmunoGen, Inc. - Pipeline by Target, 2014 27
ImmunoGen, Inc. - Pipeline by Route of Administration, 2014 28
ImmunoGen, Inc. - Pipeline by Molecule Type, 2014 29
ImmunoGen, Inc. - Pipeline Products by Mechanism of Action, 2014 30
ImmunoGen, Inc. - Recent Pipeline Updates, 2014 31
ImmunoGen, Inc. - Dormant Developmental Projects,2014 36
ImmunoGen, Inc. - Discontinued Pipeline Products, 2014 37
ImmunoGen, Inc., Key Manufacturing Facilities 41